Terms: = Breast cancer AND TRA
92 results:
1. Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models.
Teranaka R; Fujimoto H; Masuda T; Kuroda M; Aoyagi Y; Nagashima T; Takada M; Sakakibara J; Yamada H; Yamamoto H; Kubota Y; Ohtsuka M
Breast Cancer; 2023 Nov; 30(6):1018-1027. PubMed ID: 37612442
[TBL] [Abstract] [Full Text] [Related]
2. The deformation of cancer cells through narrow micropores holds the potential to regulate genes that impact cancer malignancy.
Choi JS; Lee SH; Park HB; Chun C; Kim Y; Kim KH; Weon BM; Kim DH; Kim HJ; Lee JH
Lab Chip; 2023 Aug; 23(16):3628-3638. PubMed ID: 37448298
[TBL] [Abstract] [Full Text] [Related]
3. trastuzumab potentiates doxorubicin-induced cardiotoxicity via activating the NLRP3 inflammasome in vivo and in vitro.
Wei S; Ma W; Yang Y; Sun T; Jiang C; Liu J; Zhang B; Li W
Biochem Pharmacol; 2023 Aug; 214():115662. PubMed ID: 37331637
[TBL] [Abstract] [Full Text] [Related]
4. Simultaneous Detection of Multiple Tumor-targeted Gold Nanoparticles in HER2-Positive breast Tumors Using Optoacoustic Imaging.
Samykutty A; Thomas KN; McNally M; Hagood J; Chiba A; Thomas A; McWilliams L; Behkam B; Zhan Y; Council-Troche M; Claros-Sorto JC; Henson C; Garwe T; Sarwar Z; Grizzle WE; McNally LR
Radiol Imaging Cancer; 2023 May; 5(3):e220180. PubMed ID: 37233208
[TBL] [Abstract] [Full Text] [Related]
5. Tumor resident, tra anti-viral CDR3 chemical sequence motifs are associated with a better breast cancer outcome.
Diaz MJ; Kacsoh DB; Patel DN; Yeagley M; Hsiang M; Blanck G
Genes Immun; 2023 Apr; 24(2):92-98. PubMed ID: 36805542
[TBL] [Abstract] [Full Text] [Related]
6. Anti-VEGF and Anti-EGFR Antibody Therapy on T-Cell Infiltration and TCR Variation in Metastatic Colorectal cancer.
Xu M; Tsunedomi R; Kiyotani K; Tomochika S; Furuya K; Nakajima M; Matsui H; Tokumitsu Y; Shindo Y; Yoshida S; Iida M; Suzuki N; Takeda S; Ioka T; Hazama S; Nagano H
Anticancer Res; 2023 Feb; 43(2):613-620. PubMed ID: 36697107
[TBL] [Abstract] [Full Text] [Related]
7. Chemo-Photothermal Combination Therapy of HER-2 Overexpressing breast cancer Cells with Dual-Ordered Mesoporous Carbon@Silica Nanocomposite.
Tunçel A; Yurt F
Appl Biochem Biotechnol; 2023 Mar; 195(3):1904-1927. PubMed ID: 36401724
[TBL] [Abstract] [Full Text] [Related]
8. Incidence and risk factors of infusion reactions in patients with breast cancer administered trastuzumab plus pertuzumab-based regimen.
Tabuchi Y; Tsujimoto M; Yamamoto K; Kosaka T; Sakaguchi K; Dobuchi N; Nishiguchi K; Shikata K
Cancer Chemother Pharmacol; 2023 Jan; 91(1):25-31. PubMed ID: 36401659
[TBL] [Abstract] [Full Text] [Related]
9. trastuzumab-based near-infrared photoimmunotherapy in xenograft mouse of breast cancer.
Yamashita S; Kojima M; Onda N; Yoshida T; Shibutani M
Cancer Med; 2023 Feb; 12(4):4579-4589. PubMed ID: 36259134
[TBL] [Abstract] [Full Text] [Related]
10. Cost-effectiveness Analysis of trastuzumab Emtansine as Second-line Therapy for HER2-Positive breast cancer in China.
Zhang H; Zhang Y; Huang C; Wang J
Clin Drug Investig; 2021 Jun; 41(6):569-577. PubMed ID: 33876415
[TBL] [Abstract] [Full Text] [Related]
11. Ultrasound-triggered herceptin liposomes for breast cancer therapy.
Elamir A; Ajith S; Sawaftah NA; Abuwatfa W; Mukhopadhyay D; Paul V; Al-Sayah MH; Awad N; Husseini GA
Sci Rep; 2021 Apr; 11(1):7545. PubMed ID: 33824356
[TBL] [Abstract] [Full Text] [Related]
12. Impact of oncology pharmacist services on humanistic outcome in patients with breast cancer.
Khadela A; Bhikadiya V; Vyas B
J Oncol Pharm Pract; 2022 Mar; 28(2):302-309. PubMed ID: 33491576
[TBL] [Abstract] [Full Text] [Related]
13. De-escalated Therapy Omitting Anthracyclines for Stage I HER2-positive breast cancer: A Retrospective Observational Study.
Nakamoto S; Ikeda M; Kubo S; Yamamoto M; Yamashita T
In Vivo; 2020; 34(6):3713-3718. PubMed ID: 33144488
[TBL] [Abstract] [Full Text] [Related]
14. POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway.
Wu D; Jia HY; Wei N; Li SJ
Biochem Biophys Res Commun; 2020 Dec; 533(3):533-539. PubMed ID: 32988584
[TBL] [Abstract] [Full Text] [Related]
15. Comparison of competitive cognitive models in explanation of women breast cancer screening behaviours using structural equation modelling: Health belief model and theory of reasoned action.
Firouzbakht M; Hajian-Tilaki K; Bakhtiari A
Eur J Cancer Care (Engl); 2021 Jan; 30(1):e13328. PubMed ID: 32909679
[TBL] [Abstract] [Full Text] [Related]
16. Detecting tra-1-60 in cancer via a Novel Zr-89 Labeled ImmunoPET Imaging Agent.
White JM; Kuda-Wedagedara AN; Wicker MN; Spratt DE; Schopperle WM; Heath E; Viola NT
Mol Pharm; 2020 Apr; 17(4):1139-1147. PubMed ID: 32069422
[TBL] [Abstract] [Full Text] [Related]
17. Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma.
Xu Y; Morales AJ; Cargill MJ; Towlerton AMH; Coffey DG; Warren EH; Tykodi SS
Cancer Immunol Immunother; 2019 Dec; 68(12):1979-1993. PubMed ID: 31686124
[TBL] [Abstract] [Full Text] [Related]
18. Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies.
Xiao H; Jensen PE; Chen X
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31491952
[TBL] [Abstract] [Full Text] [Related]
19. Benefit of regional anaesthesia on postoperative pain following mastectomy: the influence of catastrophising.
Zinboonyahgoon N; Vlassakov K; Lirk P; Spivey T; King T; Dominici L; Golshan M; Strichartz G; Edwards R; Schreiber K
Br J Anaesth; 2019 Aug; 123(2):e293-e302. PubMed ID: 31331591
[TBL] [Abstract] [Full Text] [Related]
20. Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.
Kanomata N; Kurebayashi J; Moriya T
Med Mol Morphol; 2019 Jun; 52(2):106-113. PubMed ID: 30317526
[TBL] [Abstract] [Full Text] [Related]
[Next]
